Bevacizumab biosimilar (AryoGen Biopharma)

贝伐珠单抗生物类似物（AryoGen Biopharma）

Report date: 2022/03/16 18:12:22

Base Information

Drug NameBevacizumab biosimilar (AryoGen Biopharma)
Drug Alias NameBevacizumab (AryoGen Biopharma)贝伐人源化单抗生物仿制药 (AryoGen Biopharma)贝伐赛珠单抗生物仿制药 (AryoGen Biopharma)AryoGen Farmad贝伐珠单抗生物仿制药 (AryoGen Biopharma) +[10] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsMetastatic breast cancerUterine Cervical NeoplasmsFallopian Tube Neoplasms +[9] 
Global Approved IndicationsMetastatic breast cancerUterine Cervical NeoplasmsFallopian Tube Neoplasms +[9] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIran
Original Approved Date2019/06/01
Country/TerritoryIran
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAryogen Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesAryogen Biopharma
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerUterine Cervical NeoplasmsFallopian Tube Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A